Abstract
Aim:
To determine a novel chemotherapeutic concept for hormone receptor-negative and HER2-positive breast cancer, a high progression form of the disease for which treatment has been difficult. A combination therapy of 5-fluorouracil (5-FU) with rapamycin (Rap) was examined.
Materials and methods:
The growth inhibitory effect of treatment was evaluated by an MTT assay and cellular signal/apoptotic pathways were investigated by Western blotting and Hoechst 33342 staining.
Results:
Rap was shown to induce an inhibitory effect on the phosphorylation of mTOR and p70S6K. The expression of thymidine synthase (TS) was decreased by Rap. The addition of 5-FU to Rap was found to increase cell death. The Hoechst 33342 assay showed that apoptosis was increased by the combination of 5-FU and Rap in comparison to 5FU alone.
Conclusion:
5-FU is more effective in combination with the TS-reducing action of Rap, even for highly HER2-expressing breast cancer cells.
MeSH terms
-
Antineoplastic Combined Chemotherapy Protocols / pharmacology*
-
Breast Neoplasms / drug therapy*
-
Breast Neoplasms / metabolism
-
Cell Line, Tumor
-
Drug Synergism
-
Extracellular Signal-Regulated MAP Kinases / metabolism
-
Female
-
Fluorouracil / administration & dosage
-
Humans
-
Intracellular Signaling Peptides and Proteins / metabolism
-
Phosphorylation / drug effects
-
Protein Serine-Threonine Kinases / metabolism
-
Proto-Oncogene Proteins c-akt / metabolism
-
Receptor, ErbB-2 / biosynthesis
-
Receptors, Estrogen / biosynthesis
-
Receptors, Progesterone / biosynthesis
-
Ribosomal Protein S6 Kinases, 70-kDa / metabolism
-
Signal Transduction / drug effects
-
Sirolimus / administration & dosage
-
TOR Serine-Threonine Kinases
Substances
-
Intracellular Signaling Peptides and Proteins
-
Receptors, Estrogen
-
Receptors, Progesterone
-
MTOR protein, human
-
Receptor, ErbB-2
-
Protein Serine-Threonine Kinases
-
Proto-Oncogene Proteins c-akt
-
Ribosomal Protein S6 Kinases, 70-kDa
-
TOR Serine-Threonine Kinases
-
Extracellular Signal-Regulated MAP Kinases
-
Fluorouracil
-
Sirolimus